Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20110211.TNBC

— · D

616928ba-bfa8-5dbe-b599-84f1efee2d8c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.490
  • MYC_TARGETS_V1+0.340
  • IL2_STAT5_SIGNALING+0.320
  • E2F_TARGETS+0.310
  • INTERFERON_GAMMA_RESPONSE+0.300
  • KRAS_SIGNALING_UP+0.290
  • COMPLEMENT+0.220
  • IL6_JAK_STAT3_SIGNALING+0.220
  • INTERFERON_ALPHA_RESPONSE+0.220
  • MITOTIC_SPINDLE+0.220

Top 10 suppressed

  • TGF_BETA_SIGNALING-0.390
  • ANGIOGENESIS-0.340
  • ESTROGEN_RESPONSE_EARLY-0.320
  • NOTCH_SIGNALING-0.310
  • MYOGENESIS-0.270
  • ADIPOGENESIS-0.240
  • ESTROGEN_RESPONSE_LATE-0.240
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.230
  • ANDROGEN_RESPONSE-0.210
  • PROTEIN_SECRETION-0.190

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120030081.TNBC
breast-umap@18
—D0.826
2MBCProject_5971_T1_RNA
breast-umap@18
—D0.818
3SRR8613734
breast-umap@18
—D0.812
4TCGA-B6-A0RT-01A-21R-A084-07
breast-umap@18
—D0.808
5MBCproject_0095_T3_RNA
breast-umap@18
—E0.808
620060324.TNBC
breast-umap@18
—D0.800
7BSR_11_0107_E3_S77
breast-umap@18
—D0.797
8SRR6013581
lung-landscapes@6
—cohortA10.794
9TCGA-A2-A0EQ-01A-11R-A034-07
breast-umap@18
—C0.791
10TCGA-43-A475-01A-11R-A24H-07
lung-landscapes@6
—cohortSQ20.790

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.490Idelalisib— uncovered
MYC_TARGETS_V10.340Inavolisib— uncovered
IL2_STAT5_SIGNALING0.320Idelalisib— uncovered
E2F_TARGETS0.310Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.300Idelalisib— uncovered
KRAS_SIGNALING_UP0.290Inavolisib— uncovered
COMPLEMENT0.220Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.220Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.220Inavolisib— uncovered
MITOTIC_SPINDLE0.220Inavolisib— uncovered
MYC_TARGETS_V20.220Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.180Idelalisib— uncovered
G2M_CHECKPOINT0.170Inavolisib— uncovered
HEDGEHOG_SIGNALING0.150Inavolisib— uncovered
PANCREAS_BETA_CELLS0.150Cobimetinib— uncovered
SPERMATOGENESIS0.100Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.100Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.080Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.060Inavolisib— uncovered
APOPTOSIS0.040Idelalisib— uncovered